RP 1664
Alternative Names: RP-1664Latest Information Update: 27 Jun 2025
At a glance
- Originator Repare Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PLK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamic and adverse events data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 03 Mar 2025 Repare Therapeutics plans to initiate a phase I/II trial for Neuroblastoma (In children) in the quarter three of 2025